Restoration of corticosteroid sensitivity in chronic obstructive pulmonary disease by inhibition of mammalian target of rapamycin

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 2, 2016, Pages 143-153

  Mitani, Akihisa ^a   Ito, Kazuhiro ^a   Vuppusetty, Chaitanya ^a   Barnes, Peter J ^a   Mercado, Nicolas ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

C Jun; Chronic obstructive pulmonary disease; Corticosteroid resistance; Mammalian target of rapamycin; Rapamycin

Indexed keywords

CIGARETTE SMOKE; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PROTEIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MITOGEN ACTIVATED PROTEIN KINASE P38; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID RESISTANCE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SMOKING; U-937 CELL LINE; WESTERN BLOTTING; ADVERSE EFFECTS; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; MIDDLE AGED; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENAL CORTEX HORMONES; AGED; DRUG RESISTANCE; FEMALE; HISTONE DEACETYLASE 2; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-JUN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIROLIMUS; SMOKING; TOR SERINE-THREONINE KINASES; U937 CELLS;

EID: 85012927476     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201503-0593OC     Document Type: Article

References (41)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-1243.
2. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009;135:173-180.
3. Ito K, Mercado N. STOP accelerating lung aging for the treatment of COPD. Exp Gerontol 2014;59:21-27.
4. Mercado N, Ito K, Barnes PJ. Accelerated ageing of the lung in COPD: new concepts. Thorax 2015;70:482-489.
5. MacNee W. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. Novartis Found Symp 2001;234:169-185. [Discussion, pp. 185-188.]
6. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 2006;174: 886-893.
7. Janssens JP, Pache JC, Nicod LP. Physiological changes in respiratory function associated with ageing. Eur Respir J 1999;13: 197-205.
8. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:342-344. [Discussion, p. 344.]
9. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliott WM, Hogg JC, Adcock IM, Barnes PJ. Targeting phosphoinositide-3-kinase-d with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182: 897-904.
10. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest 2008;134:394-401.
11. Marwick JA, Caramori G, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, Papi A. Inhibition of PI3Kd restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 2009;179: 542-548.
12. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002;99:8921-8926.
13. Mercado N, To Y, Ito K, Barnes PJ. Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-d. J Pharmacol Exp Ther 2011;337:465-470.
14. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002;109:649-657.
15. 2 adrenergic agonists reversed steroid insensitivity in severe asthma. Mol Pharmacol 2011;80:1128-1135.
16. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA 1998;95:2050-2055.
17. Goleva E, Li LB, Eves PT, Strand MJ, Martin RJ, Leung DY. Increased glucocorticoid receptor b alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 2006;173: 607-616.
18. Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010;120:76-85.
19. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011;23:744-755.
20. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14: 1296-1302.
21. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 2013;123:980-989.
22. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392-395.
23. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011;66: 191-201.
24. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009;326:140-144.
25. Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, Fergusson MM, Rovira II, Allen M, Springer DA, et al. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell Reports 2013;4:913-920.
26. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-1976.
27. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-E136.
28. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 1995;182:1951-1958.
29. Loke TK, Mallett KH, Ratoff J, O'Connor BJ, Ying S, Meng Q, Soh C, Lee TH, Corrigan CJ. Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. J Allergy Clin Immunol 2006;118:368-375.
30. Shan X, Luo H, Chen H, Daloze P, St-Louis G, Wu J. The effect of rapamycin on c-jun expression in human lymphocytes. Clin Immunol Immunopathol 1993;69:314-317.
31. Yogev O, Goldberg R, Anzi S, Yogev O, Shaulian E. Jun proteins are starvation-regulated inhibitors of autophagy. Cancer Res 2010;70: 2318-2327.
32. Wang X, Wu H, Lakdawala VS, Hu F, Hanson ND, Miller AH. Inhibition of Jun N-terminal kinase (JNK) enhances glucocorticoid receptor-mediated function in mouse hippocampal HT22 cells. Neuropsychopharmacology 2005;30:242-249.
33. 2 adrenoceptor independent protein phosphatase 2A activation. Pulm Pharmacol Ther 2012;25:201-207.
34. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-16486.
35. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999;13: 1422-1437.
36. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008;68:631-634.
37. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006;31: 342-348.
38. Reddy NM, Vegiraju S, Irving A, Paun BC, Luzina IG, Atamas SP, Biswal S, Ana NA, Mitzner W, Reddy SP. Targeted deletion of Jun/AP-1 in alveolar epithelial cells causes progressive emphysema and worsens cigarette smoke-induced lung inflammation. Am J Pathol 2012;180:562-574.
39. Taillé C, Borie R, Crestani B. Current management of lymphangioleiomyomatosis. Curr Opin Pulm Med 2011;17:374-378.
40. Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007;12:112-124.
41. Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett 2012;319:1-7.